Hofseth Biocare

Hofseth Biocare, a Norwegian-headquartered Pharmaceutical Preparation Manufacturing company, reported its total greenhouse gas emissions for 2024 as approximately 14,930,000 kg CO2e. This includes Scope 1 emissions of 1,616,000 kg CO2e, Scope 2 emissions of 15,000 kg CO2e, and Scope 3 emissions, which encompassed 11,368,000 kg CO2e from purchased goods and services, 445,000 kg CO2e from upstream transportation and distribution, and 1,453,000 kg CO2e from downstream transportation and distribution.

In 2023, Hofseth Biocare's Scope 1 emissions were 1,850,000 kg CO2e and Scope 2 emissions were 15,000 kg CO2e. For 2022, Scope 1 emissions were 2,104,000 kg CO2e and Scope 2 emissions were 15,000 kg CO2e. In 2021, the company's Scope 1 emissions were 1,810,000 kg CO2e and Scope 2 emissions were 45,000 kg CO2e. Looking further back to 2020, Hofseth Biocare reported Scope 1 emissions of 1,619,000 kg CO2e and Scope 2 emissions of 90,400 kg CO2e. The company has disclosed Scope 1 and 2 emissions data since 2020, with Scope 3 emissions data specifically reported for 2024.

Hofseth Biocare has not publicly announced any specific, quantifiable emissions reduction targets, such as Science Based Targets (SBTi), nor is it a signatory to The Climate Pledge. There are no cascaded climate commitments or emissions data from a parent organisation.